Lv3
328 积分 2023-10-12 加入
Current Progress and Challenges in the Development of Pharmacotherapy for Metabolic Dysfunction‐Associated Steatohepatitis
2个月前
已完结
The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes
2个月前
已完结
The healing bitterness of Gentiana lutea L., phytochemistry and biological activities: A systematic review
2个月前
已完结
A systematic review of the protective role of swertiamarin in cardiac and metabolic diseases
2个月前
已完结
Inhibition of IRAK4 by microbial trimethylamine blunts metabolic inflammation and ameliorates glycemic control
4个月前
已完结
Perillyl alcohol ameliorates high-fat diet-induced obese mice by modulating gut microbiota and activating Irf4-mediated brown fat thermogenesis
4个月前
已完结
Asiaticoside exerts neuroprotection through targeting NLRP3 inflammasome activation
6个月前
已完结
Hepatocellular CMPK2 promotes the development of metabolic dysfunction-associated steatohepatitis
6个月前
已完结
Hepatocellular CMPK2 promotes the development of metabolic dysfunction-associated steatohepatitis
6个月前
已完结
New advances in novel pharmacotherapeutic candidates for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) between 2022 and 2024
7个月前
已完结
皖公网安备34019202002308
